| Literature DB >> 29016861 |
Dominik Piston1,2,3, Lydia Alvarez-Erviti4, Vikas Bansal3, Daniela Gargano5, Zhi Yao6, Gyorgy Szabadkai6, Mark Odell7, M Rhyan Puno7, Benny Björkblom8, Jodi Maple-Grødem2,5, Peter Breuer9, Oliver Kaut9, Jan Petter Larsen2, Stefan Bonn3, Simon Geir Møller2,10, Ullrich Wüllner3, Anthony H V Schapira1, Matthew E Gegg1.
Abstract
DJ-1 is an oxidation sensitive protein encoded by the PARK7 gene. Mutations in PARK7 are a rare cause of familial recessive Parkinson's disease (PD), but growing evidence suggests involvement of DJ-1 in idiopathic PD. The key clinical features of PD, rigidity and bradykinesia, result from neurotransmitter imbalance, particularly the catecholamines dopamine (DA) and noradrenaline. We report in human brain and human SH-SY5Y neuroblastoma cell lines that DJ-1 predominantly forms high molecular weight (HMW) complexes that included RNA metabolism proteins hnRNPA1 and PABP1 and the glycolysis enzyme GAPDH. In cell culture models the oxidation status of DJ-1 determined the specific complex composition. RNA sequencing indicated that oxidative changes to DJ-1 were concomitant with changes in mRNA transcripts mainly involved in catecholamine metabolism. Importantly, loss of DJ-1 function upon knock down (KD) or expression of the PD associated form L166P resulted in the absence of HMW DJ-1 complexes. In the KD model, the absence of DJ-1 complexes was accompanied by impairment in catecholamine homeostasis, with significant increases in intracellular DA and noraderenaline levels. These changes in catecholamines could be rescued by re-expression of DJ-1. This catecholamine imbalance may contribute to the particular vulnerability of dopaminergic and noradrenergic neurons to neurodegeneration in PARK7-related PD. Notably, oxidised DJ-1 was significantly decreased in idiopathic PD brain, suggesting altered complex function may also play a role in the more common sporadic form of the disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29016861 PMCID: PMC5886150 DOI: 10.1093/hmg/ddx294
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150
Figure 1.Levels of dimeric and oxidised DJ-1 are altered in human PD brain. (A) SDS PAGE and western blot analysis of human post mortem tissue lysates from 10 control individuals versus 10 PD patients. Membranes were probed for total DJ-1 (Enzo mouse monoclonal) to detect monomeric and dimeric forms of the protein. An antibody that detects oxidized DJ-1 at residue C106 (oxDJ-1) was also used. β-actin was used as a loading control. (B) Quantification of the western blots shown in (A). Statistical significance was calculated by one-way ANOVA with post hoc Tukey HSD test. *P < 0.05; ***P < 0.01 vs. control.
Figure 2.DJ-1 HMW complexes are the predominant species in human brain and show evidence of oxidation. (A) Left: Soluble complexes from putamen of three healthy individuals were examined using 8-16% gradient BisTris gels and subsequent western blot analysis for total DJ-1. No monomeric DJ-1 was detectable in putamen in native lysates. However, based on its molecular weight a band perhaps representing DJ-1 homodimer was detected (indicated by arrow). Representative western blot is shown (n = 3). Right: The soluble complexes from human putamen were analysed by two dimensional BN/SDS PAGE and western blotting for total DJ-1, which was detectable in all four complexes, illustrating that the DJ-1 signal is specific. Representative western blot is shown (n = 2). (B) Soluble complexes from cortex of two healthy individuals and two PD patients were separated on 7.5% fixed percentage BisTris gels and subsequently probed for oxidized DJ-1 (ox DJ-1) and total DJ-1. Representative western blot is shown (n = 2). Protein loading of brain samples used for BN-PAGE was assessed by measuring an aliquot of each sample for β-actin by SDS-PAGE (panel underneath BN PAGE).
Figure 3.Oxidation of DJ-1 affects complex formation. (A) Soluble complexes from SH-SY5Y cells and control human putamen brain samples were separated by BN PAGE using 7.5% BisTris gels and western blot analysis for DJ-1 was performed. (B) Left: Soluble protein complexes were extracted from SH-SY5Y, scrambled control (SC1), DJ-1 knock down (KD1 and KD2) cells and separated by BN PAGE on 7.5% BisTris gels. Middle: Transfection of WT DJ-1 into the KD background rescued complex formation after 72 h. Right: Over expression of WT DJ-1 in SH-SY5Y cells slightly increased the amount of complex after 72 h compared to untransfected SH-SY5Y cells. Representative western blots are shown (n > 3). (C) To compare total amounts of monomeric, dimeric and complex bound DJ-1, soluble protein complexes were extracted from SH-SY5Y cells, KD1 and KD1 cells transfected with WT DJ-1 or C106DD DJ-1 72 h after transfection. Complexes were separated on 8-16% gradient BisTris gels and western blot analysis was performed probing for DJ-1. Representative western blot results are shown (n > 3). Protein loading of samples used for BN-PAGE was assessed by measuring an aliquot of each sample for DJ-1 and β-actin level by SDS-PAGE (panels underneath BN PAGE). (D) Left: SDS PAGE and western blot analysis was performed with KD1 cells transiently transfected with wild type DJ-1 (WT), the oxidation deficient mutant DJ-1 form C106A (A) or the oxidation mimicking DJ-1 form C106DD (DD). Membranes were probed for oxidised DJ-1 (oxDJ-1) and total DJ-1. Right: SDS PAGE and western blot analysis was performed with KD1 cells, untransfected or transiently transfected with WT or DD DJ-1 Cells were either untreated or stress treated with 1 mM H2O2 for 1 h to induce oxidation of DJ-1. Membranes were probed for oxidised DJ-1 (oxDJ-1) and β-actin. (E) Soluble protein complexes were extracted from SH-SY5Y cells, KD1, KD1 expressing WT or C106DD DJ-1and separated by BN PAGE on 8-16% BisTris gels. Cells were either stress treated with 1 mM BSO for 24 h and subsequently 1 mM H2O2 for 30 min or left untreated. Left: short exposure probing for total DJ-1. Middle: longer exposure of the same membrane. Right: Membrane probed for oxidised DJ-1 (ox DJ-1). The dotted line denotes the molecular weight of WT DJ-1 complex under basal conditions and indicates that treatment induced oxidation of DJ-1 results in a slightly higher molecular weight of the complex (F) Soluble protein complexes were extracted from SH-SY5Y cells either stress treated (1 mM BSO for 24 h and subsequently 1 mM H2O2 for 30 min) or left untreated. Samples were separated by BN PAGE on 8-16% BisTris gels and western blot analysis for total and oxidised DJ-1 was performed. Left: longer exposure probing for total DJ-1. Middle: shorter exposure of the same membrane. Right: Membrane probed for oxidised DJ-1. The arrow indicates another complex detected by total DJ-1 antibody in oxidation treated SH-SY5Y cells with the same molecular weight as C106DD DJ-1 complex.
Figure 4.DJ-1 complexes are not detected upon expression of the PD associated DJ-1 mutant L166P. (A) Soluble protein complexes were extracted from KD1 cells transfected with WT DJ-1 or L166P DJ-1 72 h after transfection. Complexes were separated on 8–16% gradient BisTris gels and western blot analysis was performed probing for DJ-1. In cells expressing the PD associated mutation DJ-1 L166P the complex was absent. Representative western blot results are shown (n = 2). (B) Analysis of total DJ-1 levels in the same samples by SDS PAGE and western blotting revealed that introduction of WT-DJ-1 in to KD1 cells significantly increased total DJ-1 levels. However total DJ-1 levels in KD1 cells expressing DJ-1 L166P were almost as low as in KD1 cells alone. β-actin was used as loading control. Representative western blot is shown.
Top up and down regulated mRNA targets in DD cells when compared to WT cells that showed inverse correlation with their respective miRNAs
| Gene | Description | Pathway | log2 fold change | |
|---|---|---|---|---|
| Down regulated | ||||
| SGK1 | Serum and glucocorticoid-regulated kinase 1 | HD signaling | −2.73 | 1.47E-68 |
| TGM2 | Tissue transglutaminase 2 | HD signaling | −2.28 | 2.66E-75 |
| ITGA5 | Integrin alpha-5 | Apoptosis | −2.16 | 3.43E-09 |
| CPLX2 | Complexin-2 | HD signaling | −1.94 | 6.17E-36 |
| SYK | Spleen tyrosine kinase | Inflammation | −1.87 | 8.50E-36 |
| PRKCA | Protein kinase C alpha type | Apoptosis | −1.76 | 5.36E-157 |
| GRIP1 | Glutamate receptor-interacting protein 1 | Glutamate receptor signaling | −1.71 | 3.12E-48 |
| GRIN1 | Glutamate receptor ionotropic, NMDA 1 | Dopamine/cAMP signaling; Glutamate receptor signaling | −1.56 | 4.00E-03 |
| CAPN6 | Calpain-6 | Apoptosis | −1.54 | 4.05E-05 |
| KCNJ3 | G protein-activated inward rectifier potassium channel 1 | Dopamine/cAMP signaling | −1.44 | 1.83E-02 |
| GRM2 | Metabotropic glutamate receptor 2 | Glutamate receptor signaling | −1.31 | 3.19E-02 |
| CACNA1C | Voltage-dependent L-type calcium channel subunit alpha-1C | Dopamine/cAMP signaling | −1.01 | 4.08E-04 |
| GRM7 | Metabotropic glutamate receptor 7 | Glutamate receptor signaling | −0.89 | 1.18E-11 |
| Up regulated | ||||
| SLC18A1/ VMAT1 | Solute carrier 18A1/vesicular monoamine transporter 1 | Dopamine receptor signalling | 1.66 | 1.75E-229 |
| MAP3K5/ ASK1 | Mitogen-activated protein kinase kinase kinase 5/Apoptosis signal-regulating kinase 1 | Apoptosis | 1.16 | 4.64E-20 |
| CYGB | Cytoglobin | Superoxide radical degradation | 1.04 | 1.29E-29 |
| MYCN | N-myc proto-oncogene protein | ERK/MAPK signaling | 0.94 | 7.32E-10 |
| HSPA1A | Heat shock 70 kDa protein 1A | HD signaling | 0.76 | 7.59E-08 |
| CCND1 | Cyclin-D1 | cell cycle control (PI3/Akt) | 0.63 | 5.77E-42 |
| MAPK11 | Mitogen-activated protein kinase 11 | PD signaling | 0.63 | 9.45E-11 |
| SLC1A1 | Solute carrier 1A1/Excitatory amino acid transporter 3 | Glutamate receptor signaling | 0.61 | 1.78E-05 |
| THEM4 | Acyl-coenzyme A thioesterase | Cell cycle control (PI3/Akt) | 0.55 | 1.92E-06 |
| BMPR1B | Bone morphogenetic protein receptor type-1B | PTEN signaling | 0.48 | 3.92E-09 |
| Hsc70 | Heat shock 70 kDa protein 8/Heat shock cognate 71 kDa protein | HD signaling | 0.46 | 3.27E-16 |
| DRD2 | Dopamine receptor D2 | Dopamine receptor signalling; Dopamine/cAMP signaling | 0.45 | 7.31E-04 |
| KCNJ8 | ATP-sensitive inward rectifier potassium channel 8 | Dopamine/cAMP signaling | 0.44 | 7.68E-07 |
| PIK3R1 | Phosphatidylinositol 3-kinase regulatory subunit alpha | HD signaling | 0.43 | 1.26E-07 |
| RPS24 | 40S ribosomal protein S24 | PD signaling | 0.38 | 6.27E-03 |
| IFT57 | Intraflagellar transport protein 57 homolog | HD signaling | 0.38 | 6.99E-07 |
Top up and down regulated mRNA targets in DD cells when compared to WT cells irrespective of miRNAs
| Gene | Description | log2 fold change | ||
|---|---|---|---|---|
| Down regulated | ||||
| Monooxygenase, DBH-like 1 | −4.47 | 4.37E-55 | ||
| Corin, serine peptidase | −4.24 | 5.53E-30 | ||
| Gamma-aminobutyric acid (GABA) A receptor, beta 3 | −4.17 | 1.13E-41 | ||
| Protein phosphatase 2, regulatory subunit B, gamma | −3.88 | 1.24E-12 | ||
| 5-Hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | −2.94 | 3.41E-14 | ||
| Dickkopf WNT signaling pathway inhibitor 2 | −2.77 | 1.23E-294 | ||
| Serum/glucocorticoid regulated kinase 1 | −2.73 | 1.47E-68 | ||
| Solute carrier family 18 (vesicular acetylcholine) 3 | −2.54 | 6.83E-12 | ||
| Glutamate decarboxylase 1 (brain, 67kDa) | −2.44 | 4.81E-34 | ||
| Glutamate receptor, metabotropic 8 | −2.35 | 3.52E-05 | ||
| Cholinergic receptor, muscarinic 2 | −2.3 | 1.15E-11 | ||
| Polo-like kinase 2 | −2.18 | 4.14E-79 | ||
| Monoamine oxidase A | −0.43 | 2.98E-08 | ||
| Up regulated | ||||
| Dopa decarboxylase (aromatic L-amino acid decarboxylase) | 1.94 | 3.16E-287 | ||
| Insulin-like growth factor 2 (somatomedin A) | 1.93 | 1.04E-71 | ||
| MIR143 host gene (non-protein coding) | 1.89 | 1.95E-03 | ||
| DBH antisense RNA 1 | 1.77 | 1.01E-53 | ||
| Solute carrier family 18 (vesicular monoamine) 1 | 1.66 | 1.75E-229 | ||
| 5-Hydroxytryptamine (serotonin) receptor 1E, G protein-coupled | 1.54 | 5.07E-03 | ||
| Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | 1.35 | 6.73E-201 | ||
| Solute carrier family 6 (neurotransmitter transporter, noradrenalin) 2 | 0.64 | 6.07E-49 | ||
| Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter) 1 | 0.61 | 1.78E-05 | ||
| Dopamine receptor D2 | 0.45 | 7.31E-04 | ||
Figure 5.VMAT1, DBH and ASK1 mRNA in oxidized and DJ-1 KD cells. qPCR was performed on SH-SY5Y cells, KD1, WT and DD cells and relative expression calculated. Data were normalized to β-actin mRNA levels. (A) mRNA levels in DD cells are expressed as % WT levels (n = 4–5). (B) KD1 mRNA levels are expressed as % SH-SY5Y cells (n = 4–5). (C) SH-SY5Y cells treated with oxidative stress (1 mM BSO for 24 h and 1 mM H2O2 for 30 min; OX) and expressed as % of untreated SH-SY5Y (n = 3–5). (D) mRNA levels in KD1 cells treated with oxidative stress and expressed as % untreated KD1 cells (n = 3–5). Statistical significance calculated using Students T-test versus respective control. *P < 0.05 vs. SH/WT; **P < 0.01 vs. WT; ***P < 0.001 vs. SH; n.s., non-significant.
Figure 6.Knock down of DJ-1 affects the dopaminergic and noradrenergic system. (A) Overview of catecholamine synthesis pathways. Abbreviations: tyrosine hydroxylase (TH), dopa decarboxylase (DDC), dopamine beta hydroxylase (DBH), phenylethanolamine-N-methyltransferase (PNMT). (B,C) Results of catecholamine ELISA to measure intracellular levels of dopamine (DA) and noradrenaline (NOR). Catecholamine levels were calculated as pg/mg protein. Results are expressed as percent of SH-SY5Y cells (n = 3). Statistical significance was determined by one-way ANOVA with post hoc Tukey HSD test. *P < 0.05 vs. SH; **P < 0.01 vs. SH; n.s., non-significant.
Figure 7.Treatment of cells with oxidative stress increased DA and NOR levels. (A,B) Catecholamine ELISAs to measure intracellular levels of noradrenaline (NOR) and dopamine (DA) in WT and DD cells following treatment with oxidative stress (OX; 1 mM BSO for 24 h and 1 mM H2O2 for 30 min). Catecholamine levels were calculated as pg/mg protein (n = 3). Statistical significance determined by Students T-test compared to respective control cell line. *P < 0.05; **P < 0.01; n.s., non-significant.